Meta-analysis of 11 studies in metastatic uveal melanoma (455 hepatic perfusion, 125 best alternative care patients): perfusion was associated with higher response (47.4% vs 6.0%) and 1-year PFS (30.1% vs 6.4%) but no clear survival benefit (1-year OS 65.5% vs 64.3%).
Meta-analysisn = 580
van den Hoek et al. Percutaneous hepatic perfusion versus best alternative care as treatment for metastatic uveal melanoma: A meta-analysis